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Statistical Methods in Translational Medicine
Shein-Chung Chow,1,3* Siu-Keung Tse,2 Min Lin1
This study focuses on strategies and statistical considerations for assessment of translation in language
(e.g. translation of case report forms in multinational clinical trials), information (e.g. translation of 
basic discoveries to the clinic) and technology (e.g. translation of Chinese diagnostic techniques to well-
established clinical study endpoints) in pharmaceutical/clinical research and development. However, most
of our efforts will be directed to statistical considerations for translation in information. Translational
medicine has been defined as bench-to-bedside research, where a basic laboratory discovery becomes 
applicable to the diagnosis, treatment or prevention of a specific disease, and is brought forth by either 
a physician–scientist who works at the interface between the research laboratory and patient care, or by a
team of basic and clinical science investigators. Statistics plays an important role in translational medicine
to ensure that the translational process is accurate and reliable with certain statistical assurance. Statistical
inference for the applicability of an animal model to a human model is also discussed. Strategies for selec-
tion of clinical study endpoints (e.g. absolute changes, relative changes, or responder-defined, based on 
either absolute or relative change) are reviewed. [J Formos Med Assoc 2008;107(12 Suppl):S61–S73]
Key Words: bench-to-bedside, biomarker development, lost in translation, one-way translation, 
two-way translation
ORIGINAL ARTICLE
In early 2000, the United States Food and Drug
Administration (FDA) presented the Critical Path
Initiative to assist sponsors to identify possible
causes of the scientific challenges underlying the
medical product pipeline problems. The Critical
Path Opportunities List released by the FDA on 16
March 2006 identified better evaluation tools
and streamlining clinical trials as the top two
areas to bridge the gap between the quick pace of
new biomedical discoveries and the slower pace
at which those discoveries are currently devel-
oped into therapies. This has led to the consider-
ation of the use of adaptive design methods in
clinical development and the focus of translational
medicine (or science/research), which attempt
not only to identify the best clinical benefit of a
drug product under investigation, but also to in-
crease the probability of success. Statistical meth-
ods for the use of adaptive trial designs in clinical
development have been reported.1,2 In this arti-
cle, however, we will focus on statistical methods
that are commonly employed in translational
medicine.
Chow has classified translational medicine into
three areas, namely, translation in language, trans-
lation in information, and translation in (med-
ical) technology.3 Translation in language refers
to possible lost in translation of informed consent
and/or case report forms in multinational clinical
trials. Lost in translation is commonly encountered
because of differences in language, perception, cul-
ture and medical practices. A typical approach for
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assessment of the possible lost in translation is
to first translate the informed consent and/or the
case report forms by an experienced expert, and
then translate them back by a different experi-
enced but independent expert. The back-translated
version is then compared with the original ver-
sion for consistency. If the back-translated version
passes the test for consistency, then it is validated
through a small scale pilot study before it is 
applied to the intended multinational clinical
trial. Translation in information is referred to as
bench-to-bedside in translational science/research,
which is also known as translational medicine.
Translation in technology includes biomarker
development and translation in diagnostic pro-
cedures between traditional Chinese and Western
medicine. In this article, we will focus on statisti-
cal methods for translation in information and
technology. Note that, in practice, translational
medicine is often divided into two areas, namely,
discovery and clinical translational medicine. Dis-
covery translational medicine refers to biomarker
development, bench-to-bedside, and animal ver-
sus human models, while clinical translational
medicine includes translation among study end-
points, translation in technology, and generaliza-
tion from a target patient population to another.
In the next section on Biomarker Development,
statistical methods for biomarker development,
especially for optimal variable screening in mi-
croarray analysis, are outlined. Also included in this
section is a cross-validation method for model
selection and validation. The section on Bench-
to-Bedside discusses the ideas of a one-way and
two-way translation process in pharmaceutical/
clinical development. Whether or not an estab-
lished animal model is predictive of a human
model is examined in the section on Animal vs.
Human Models. The Translation in Study Endpoints
section summarizes translation among different
study endpoints. Issues that are commonly en-
countered in translation in technology are de-
scribed in the section on Bridging Studies. Also
included in this section is the generalization of
results obtained from a target patient population
to another similar but different target patient
population. This is followed by some concluding
remarks.
Biomarker Development
A biomarker is an objectively measured and eval-
uated characteristic that is an indicator of normal
biological processes, pathogenic processes, or phar-
macologic responses to a therapeutic intervention.
Biomarkers can be classified into classifier, prog-
nostic and predictive markers. A classifier marker
usually does not change over the course of the
study and can be used to distinguish patients who
would benefit from the treatment from those who
would not. A typical example is a DNA marker
for population selection in the enrichment process
of clinical trials. A prognostic marker informs the
clinical outcomes, which is independent of treat-
ment. A predictive marker informs the treatment
effect on the clinical endpoint, which could be
population-specific. That is, a predictive marker
can be predictive for population A but not popu-
lation B. It should be noted that correlation be-
tween biomarkers and true endpoints make a
prognostic marker. However, correlation between
biomarkers and true endpoints does not make a
predictive biomarker.
In clinical development, a biomarker can be
used to select the right population, identify the
natural course of disease, assist in early detection
of disease, and help develop personalized medi-
cine. The utilization of biomarkers may lead to a
better target population, detection of a large ef-
fect size with a smaller sample size, and timely
decision making. As indicated in the FDA Critical
Path Initiative Opportunity List, better evaluation
tools call for biomarker qualification and stan-
dards. Statistical methods for early stage bio-
marker qualification include, but are not limited to:
(1) distance-dependent K-nearest neighbors (DD-
KNN); (2) K means clustering; (3) single/average/
complete linkage clustering; and (4) distance-
dependent Jarvis–Patrick clustering. More infor-
mation can be found at http://www.ncifcrf.gov/
human_studies.shtml.
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We will now review statistical methods that are
commonly used in biomarker development for
optimal variable screening. The selected variables
will then be used to establish a predictive model
through a model selection/validation process.
Optimal variable screening
DNA microarrays have been used extensively in
medical practice. Microarrays identify a set of can-
didate genes that are possibly related to a clinical
outcome of a disease or a medical treatment. How-
ever, there are many more candidate genes than
the number of available samples (the sample size)
in almost all studies, which leads to an irregular
statistical problem in disease diagnosis or treat-
ment outcome prediction. Some available statis-
tical methods deal with one single gene at a time,4
which clearly does not provide the best solution
for polygenic diseases. In practice, a meta-analysis
and/or combining several similar studies is often
considered to increase sample size. These ap-
proaches may, however, not be appropriate be-
cause: (1) the combined dataset may still be much
too small; and (2) there may be heteroscedastic-
ity among the data from different studies. Alter-
natively, Shao and Chow proposed an optimal
variable screening approach for dealing with the
situation in which the number of variables (genes)
is much larger than the sample size.5
Let y be a clinical outcome of interest and x
be a vector of p candidate genes that are possibly
related to y. Shao and Chow simply considered
inference on the population of y conditional on x,
and noted that their proposed method can be ap-
plied to the unconditional analysis (i.e. both y
and x are random).5 Consider the following model:
(1)
where b is a p-dimensional vector and the distri-
bution of e is independent of x with E(e) = 0 and
E(e2) = s 2. Under model (1), assume that there is
a positive integer p0 (which does not depend on
n), such that only p0 components of b are non-
zero. Furthermore, b is in the linear space gener-
ated by the rows of XX for sufficiently large n,
where X is the n × pn matrix whose ith row is xi¢. 
In addition, assume that there is a sequence {zn}
of positive numbers such that zn∞ and lin =bizn,
where lin is the ith non-zero eigen value of X’X,
I=1,…,n, and {bi} is a sequence of bounded posi-
tive numbers. Note that in many problems, zn =n.
Furthermore, there exists a constant c > 0 such
that For the estimation of b, Shao and
Chow considered the following ridge regression
estimator:5
(2)
where Y = (y1,…,yn), is the identity matrix of
order pn and hn > 0 is the ridge parameter. The bias
and variance of are given by:
and
Let bi and be the ith component of b and , re-
spectively. Under the assumptions as described
earlier, we have (i.e. is consis-
tent for bi in mean squared error) if hn is suitably 
chosen. Thus, we have
(3)
Hence, var( ) 0 for all i as long as hn ∞. Note 
that the analysis of the bias of is more compli-
cated. Let Γ be an orthogonal matrix such that
where Λn is a diagonal matrix whose ith diagonal
element is lin, and 0l × k is the l × k matrix of 0’s.
Then, it follows that
(4)
where A is a pn × pn diagonal matrix whose first n
diagonal elements are and the 
last diagonal elements are all equal to 1. Under
the above mentioned assumptions, combining the 
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results for variance and bias of , i.e. equations
(3) and (4), it can be shown that for all i
if hn is chosen so that hn∞ at a rate slower 
than zn (e.g. ). Based on this result, Shao
and Chow proposed the following optimal vari-
able screening procedure:5 let {an} be a sequence
of positive numbers satisfying an 0. For each
fixed n, we screen out the ith variable if and only
if 
Note that, after screening, only variables asso-
ciated with are retained in the model as
predictors. The idea behind this variable screening
procedure is similar to that in the Lasso method.6
Under certain conditions, Shao and Chow showed
that their proposed optimal variable screening
method is consistent in the sense that the prob-
ability that all variables (genes) unrelated to y,
which will be screened out, and all variables
(genes) related to y, which will be retained, is 1
as n tends to infinity.5
Model selection and validation
Suppose that n data points are available for se-
lecting a model from a class of models. Several
methods for model selection are available in the
literature. These methods include, but are not
limited to, Akaike information criterion (AIC),7,8
the Cp,9 and the Jackknife and the bootstrap.10
These methods, however, are not asymptotically
consistent in the sense that the probability of se-
lecting the model with the best predictive ability
does not converge to 1 as the total number of ob-
servations n∞. Alternatively, Shao proposed a
method for model selection and validation using
the method of cross-validation.11 The idea of
cross-validation is to split the dataset into two
parts. The first part contains nc data points, which
will be used for fitting a model (model construc-
tion), whereas the second part contains nv = n − nc
data points, which are reserved for assessing the
predictive ability of the model (model validation).
It should be noted that all of the n = nc + nv data,
not just nv are used for model validation. Shao
showed that all of the methods of AIC, Cp,
Jackknife and bootstrap are asymptotically equiv-
alent to the cross-validation with nv = 1, denoted
by CV(1), although they share the same deficiency
of inconsistency.11 Shao indicated that the incon-
sistency of the leave-one-out cross-validation can
be rectified by using leave-nv-out cross-validation
with nv satisfying nv/n 1 as n∞.11
In addition to the cross-validation with nv = 1,
denoted by CV(1), Shao also considered the
other two cross-validation methods, namely, a
Monte Carlo cross-validation with nv(nv ≠ 1), de-
noted by MCCV(nv), and an analytic approxi-
mate CV(nv), denoted by APCV(nv). MCCV(nv) is
a simple and easy method that utilizes the me-
thod of Monte Carlo by randomly drawing (with
or without replacement) a collection ℜ of b sub-
sets of {1,…,n} that have size nv and select a
model by minimizing
On the other hand, APCV(nv) selects the optimal
model based on the asymptotic leading term of
balance incomplete CV(nv), which treats each
subset as a block and each i as a treatment. Shao
compared these three cross-validation methods
through a simulation study under the following
model with five variables with n = 40:11
where ei are independent and identically distrib-
uted (i.i.d.) normal variable with mean 0 and
variance 1, i.e. N(0,1), xki is the ith value of the kth
prediction variable xk, xlk = 1, and the values of xki,
k = 2,…,5, I = 1,…,40, are taken from an example
in Gunst and Mason.12 Note that there are 31
possible models, and each model is denoted by a
subset of {1,…,5} that contains the indices of
the variable xk in the model. Shao indicated that
MCCV(nv) has the best performance among the
three methods under study, except for the case in
which the largest model is the optimal model.
APCV(nv) is slightly better than the CV(1) in all
cases.11 CV(1) tends to select unnecessarily large
models. The probability of selecting the optimal
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model by using the CV(1) could be very low 
(e.g. < 0.5).
Remarks
In practice, it is suggested that the optimal variable
screening method proposed by Shao and Chow
be applied to select a few relevant variables, say
5–10.5 After this, apply the cross-validation
method to select the optimal model based on
linear model selection or non-linear model selec-
tion.13 The selected model can then be validated
based on the cross-validation methods as de-
scribed in the previous subsection. Note that the
method for variable screening described in this
section is very similar to the method based on
least absolute shrinkage and selection operator.
The selection of biomarker should be based
on the consideration of the diagnostic accuracy
and time for evaluation. However, the FDA ap-
proved MammaPrint® has a very poor positive
predictive value for metastatic disease. Thus, it 
is suggested that the development of biomarker
for long-term prognosis of clinical outcomes
should be based on the prediction of treatment
effect.
Bench-to-Bedside
Pizzo defined translational medicine as bench-
to-bedside research, wherein a basic laboratory
discovery becomes applicable to the diagnosis,
treatment or prevention of a specific disease, and
is brought forth by either a physician–scientist
who works at the interface between the research
laboratory and patient care, or by a team of basic
and clinical science investigators.14 Thus, transla-
tional medicine refers to the translation of basic
research discoveries into clinical applications.
More specifically, translational medicine takes
the discoveries from basic research to a patient
and measures an endpoint in a patient. Recently,
scientists have become increasingly aware that
this bench-to-bedside approach to translational
research is a two-way street. Scientists provide
clinicians with new tools for use with patients
and for assessment of their impact, and clinical
researchers make novel observations about the
nature and progression of disease that often stim-
ulate basic investigations. As indicated by Pizzo,
translational medicine can also have a much
broader definition, referring to the development
and application of new technologies, biomedical
devices, and therapies in a patient-driven environ-
ment such as clinical trials, in which the empha-
sis is on early patient testing and evaluation.14
Thus, translational medicine also includes epi-
demiologic and health-outcomes research and
behavioral studies that can be brought to the
bedside or ambulatory setting.
Mankoff et al pointed out that there are three
major obstacles to effective translational medicine
in practice.15 The first is the challenge of translat-
ing basic science discoveries into clinical studies.
The second hurdle is the translation of clinical
studies into medical practice and health care 
policy. A third obstacle to effective translational
medicine is philosophical. It may be a mistake to
think that basic science (without observations
from the clinic and without epidemiologic find-
ings of possible associations between different
diseases) will efficiently produce the novel thera-
pies for human testing. Pilot studies such as non-
human and non-clinical studies are often used to
transform therapies developed using animal mod-
els to a clinical setting. Statistical processes play
an important role in translational medicine. In
particular, we define a statistical process of trans-
lational medicine as a translational process for:
(1) determining association between some inde-
pendent parameters observed in basic research
discoveries and a dependent variable observed
from clinical application; (2) establishing a pre-
dictive model between the independent parame-
ters and the dependent response variable; and
(3) validating the established predictive model.
As an example, in animal studies, the independ-
ent variables may include in vitro assay results,
pharmacologic activities such as pharmacokinet-
ics and pharmacodynamics, and dose toxicities,
and the dependent variable could be a clinical
outcome (e.g. a safety parameter).
Statistical methods in translational medicine
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If the information observed with basic research
discoveries is translated to the clinic, it is usually
referred to as a one-way translation process. How-
ever, as indicated by Pizzo, the translational pro-
cess should be a two-way translation, in which
information obtained in clinical study can also
be translated back to basic research discoveries.
Tse has described the statistical process in how to
validate a translational process, either one-way or
two-way, based on some probability-based criteria.
Furthermore, a measure to assess the degree of
lost in translation has also been proposed.16
Animal vs. Human Models
In translational medicine, a commonly asked ques-
tion is whether an animal model is predictive of
a human model. To address this question, we may
assess the similarity between an animal model
(population) and a human model (population).
For this purpose, we first establish an animal
model to bridge the basic research discovery (x)
and clinic (y). For illustration purposes, consider
a one-way translation process of y = b0 + b1x + e.
Let be the predictive model obtained
from the one-way translation based on data from
an animal population. Thus, for a given x0,
follows a distribution with mean my
and Under the predictive model ,
denoted by (my, sy) the target population, and as-
sume that the predictive model works for the tar-
get population. Thus, for an animal population,
my =manimal and sy =sanimal, while for a human popu-
lation, my = mhuman and sy = shuman. Assuming that
the linear predictive model can be applied to both
animal and human populations, we can link the
animal and human models by the following:
and
In other words, we expect that there are dif-
ferences in population mean and population
standard deviation (SD) under the predictive
model caused by possible differences in response
between animals and humans. As a result, the 
effect size adjusted for SD under the human 
population can be obtained as follows:
where  = (1 + e/manimal)/C. Chow et al refer to 
as a sensitivity index when changing from one
target population to another.17 As can be seen,
the effect size under the human population is in-
flated (or reduced) by the factor . If e = 0 and
C = 1, we then claim that there is no difference be-
tween the animal and human populations. Thus,
the animal model is predictive of the human
model. Note that the shift and scale parameters
(i.e. e and C) can be estimated by
and
respectively, in which and , 
are estimates of (manimal, sanimal) and (mhuman,
shuman), respectively. Thus, the sensitivity index can
be assessed as follows:
In practice, there may be a shift in population
mean (i.e. e) and/or in population SD (i.e. C).
Chow et al indicated that shifts in population
mean and population SD can be classified into
the following four cases, in which: (1) both e and
C are fixed; (2) e is random and C is fixed; (3) e is
fixed and C is random; and (4) both e and C are
random. For the case in which both e and C are
fixed, (v) can be used for the estimation of .18
Chow et al derived statistical inference of  for
the case in which e is random and C is fixed by
assuming that y conditional on m follows a nor-
mal distribution, N(m, s 2). That is,
where m is distributed as N(mm, ), and s, mm
and sm are some unknown constants. It can be
s m
2
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verified that y follows a mixed normal distribu-
tion with mean mm and variance s 2 + That is, 
y ∼ N(mm, s2 + As a result, the sensitivity index 
can be assessed based on data collected from
both animal and human populations under the
predictive model.
Note that for other cases in which C is 
random, the above method can also be derived
similarly. The assessment of sensitivity index can
be used to adjust the treatment effect to be 
detected under a human model when applying
an animal model to a human model, especially
when there is a significant or major shift between
an animal and human population. In practice, 
it is of interest to assess the impact of the sensi-
tivity index on lost in translation and the proba-
bility of success. This, however, requires further
research.
Translation in Study Endpoints
In clinical trials, it is not uncommon that a study
is powered based on expected absolute change
from baseline of a primary study endpoint, but
the collected data are analyzed based on relative
change from baseline (e.g. percent change from
baseline) of the primary study endpoint. In many
cases, the collected data are analyzed based on
the percentage of patients who show some im-
provement (i.e. responder analysis). The defini-
tion of a responder may be based on either
absolute change from baseline or relative change
from baseline of the primary study endpoint. It
is controversial in terms of the interpretation of
the analysis results, especially when a significant
result is observed based on a study endpoint (e.g.
absolute change from baseline, relative change
from baseline, or responder analysis), but not on
the other study endpoint (e.g. absolute change
from baseline, relative change from baseline, or
responder analysis). In practice, it is of interest to
explore how an observed significant difference of
a study endpoint (e.g. absolute change from base-
line, relative change from baseline, or responder
analysis) can be translated to that of the other
study endpoint (e.g. absolute change from base-
line, relative change from baseline, or responder
analysis).
Power analysis and sample size calculation
The power analysis for sample size calculation
has an immediate impact on the assessment 
of treatment effect based on different study end-
points. For example, sample size required in
order to achieve the desired power based on the
absolute change may be very different from that
obtained based on the percent change, or the
percentage of patients who show an improve-
ment based on the absolute change or relative
change at the a level of significance. Denote the
measurements of the ith subject before and after
the treatment by w1i and w2i, respectively. For 
illustration purposes, assume that w1i are log 
normal distributed, i.e. logw1i ∼ N(m1, s 2). Let
, where , and 
w1i and are independent for 1 ≤ i, j ≤ n. It 
follows that log(w2i − w1i) ∼ N(m1 + m2, 2s 2) and 
. Define Xi and Yi as
Xi = log(w2i − w1i), Then Xi and 
Yi represent the logarithm of the absolute and
relative changes of the measurements before 
and after treatment. It can be shown that both 
Xi and Yi are normally distributed.
Let mAC and mRC be the population means 
of the logarithm of the absolute and relative
change of a primary study endpoint of a given
clinical trial, respectively. Thus, the hypotheses
of interest based on the absolute change are
given by
where d0 is the difference of clinical importance.
For the relative change, the hypotheses of interest
are given by
where 0 is the difference of clinical importance.
In practice, for a specific value of d, where d > d0,
it would be of interest to determine what value
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of  (with  >0) would be equivalent to d
clinically.
In addition, if we consider that a patient is a
responder if the logarithm of his/her absolute
change of the primary study endpoint is greater
than δ, then it is of interest to test the following
hypotheses:
where PAC is the proportion of patients whose
logarithm of absolute change of the primary study
endpoint is greater than d. In practice, we may
claim superiority (clinically) of the test treatment
if we reject the null hypothesis at h = 50%, and
favor the alternative hypothesis that PAC is > 50%.
However, this lacks statistical justification. For a
noninferiority (or superiority) trial, it is often of
interest to know how the selection of a noninfe-
riority margin of mAC can be translated to the non-
inferiority margin of PAC. Similarly, for the relative
change, the hypotheses of interest are given by
where PRC is the proportion of patients whose
logarithm of the relative change of the primary
study endpoint is greater than d. Figures 1–4 are
plots of (d − d0) versus n (sample size), ( −0)
versus n, ln d versus n, and ln  versus n, respec-
tively. In particular, a = 0.05, power = 1 − b = 0.8,
and h = 0.5, which provide a better understand-
ing of the required sample size to achieve a pre-
determined power level for the above four sets of
hypotheses.
An example
As an example, consider a clinical trial for 
evaluation of possible weight reduction of a test
treatment in female patients. Weight data from
10 subjects are given in Table 1. As seen in Table 1,
mean absolute change and mean percent change
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H P vs H PAC a AC03 3: . : ,= >h h
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from pretreatment are 5.3 lbs and 4.8%, respec-
tively. If a subject is considered a responder if there
is weight reduction of > 5 lbs (absolute change) or
> 5% (relative change), the response rates based
on absolute and relative change are given as 40%
and 30%, respectively. For illustration purposes,
Table 2 summarizes the sample sizes required for
achieving the desired power for detecting a clini-
cally meaningful difference, say, by an absolute
change of 5.5 lbs and a relative change of 5.5%,
for the two study endpoints respectively.
As shown in Table 2, a sample size of 190 is
required for achieving an 80% power for detect-
ing a difference of 5.5 lbs (posttreatment absolute
change from pretreatment) at the 5% level of 
significance, while a much larger sample size of
95 is required in order to have an 80% power for
detecting a difference of 5.5% (relative change
between posttreatment and pretreatment) at the
5% level of significance. Based on responder analy-
sis, the results are different. Based on the analysis
of responders, defined as subjects who have
weight reduction ≥ 5.5 lbs, a total sample size of
54 subjects is needed for detecting a 50% 
improvement at the 5% level of significance. On
the other hand, if we define a responder as a sub-
ject who has a weight reduction ≥ 5.5%, then a
total sample size of 52 subjects is required for
achieving a 50% improvement at the 5% level of
significance.
Remarks
As discussed above, sample sizes required for
achieving the desired power for detecting a clini-
cally meaningful difference at the 5% level of 
significance may be very different depending
upon the choice of study endpoint and a clini-
cally meaningful difference. In practice, it will be
more complicated if the intended trial is to estab-
lish noninferiority. In this case, sample size cal-
culation will also depend on the selection of the
noninferiority margin. To ensure the success of
the intended clinical trial, the sponsor will usu-
ally evaluate carefully several clinical strategies
when selecting the type of study endpoint, clini-
cally meaningful difference, and noninferiority
margin during the stage of protocol development.
Commonly considered study endpoints are:
• measure based on absolute change;
• measure based on relative change;
• proportion of responders defined based on
absolute change;
• proportion of responders defined based on
relative change.
In some cases, investigators may consider a
composite endpoint based on absolute and re-
lative change. For example, in clinical trials for
evaluation of the efficacy and safety of a com-
pound for treating patients with active ulcerative
colitis, a study endpoint utilizing the so-called
Mayo score is often considered. The investigator
may define a subject as a responder if he/she has
a decrease from baseline in the total score of at
least 3 points and at least 30%, with an accom-
panying decrease in the subscore for rectal bleed-
ing of at least 1 point or absolute subscore for
rectal bleeding of 0 or 1 at day 57. Note that the
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Table 2. Sample size calculation
Study endpoint
Clinically meaningful 
Sample size required
difference
Absolute change 5 lb 190
Relative change 5% 95
Responder 1* 50% improvement 54
Responder 2† 50% improvement 52
*Responder is defined based on absolute change ≥ 5.5 lbs; †responder is defined based
on relative change ≥ 5.5%.
Table 1. Weight data from 10 female subjects
Pretreatment Posttreatment
Absolute Relative 
change change (%)
110 106 4 3.6
90 80 10 11.1
105 100 5 4.8
95 93 2 2.1
170 163 7 4.1
90 84 6 6.7
150 145 5 3.3
135 131 4 3.0
160 159 1 0.6
100 91 9 9.0
120.5 (30.5) 115.2 (31.5) 5.3 4.8
Mayo scoring system for assessment of ulcerative
colitis activity consists of the three domains of:
Mayo score; partial Mayo score; and mucosal
healing.19
In addition to the four types of study end-
points which are derived from the clinical data
collected from the sample patient population,
clinically meaningful differences or noninferior-
ity margins that we would like to detect or estab-
lish may be based on absolute or relative change.
For example, based on responder analysis, we
may wish to detect a 30% difference in response
rate or to detect a 50% relative improvement in
response rate. As a result, there are a total of eight
clinical strategies for assessment of the treatment
effect. In practice, some strategies may lead to the
success of the intended clinical trial (i.e. achieve
the study objectives with the desired power),
while some strategies may not. A common prac-
tice for the sponsor is to choose the strategy that
corresponds to their best interest. However, regu-
latory agencies may challenge the sponsor as to
the inconsistent results. This has raised the fol-
lowing questions. First, how do we translate the
clinical information among different study end-
points since they are obtained based on the same
data collected from the some patient popula-
tion? Second, which study endpoint is telling the
truth? These questions, however, remain unan-
swered. More research is required. The current
regulatory position is to require the sponsor to
prespecify which study endpoint will be used for
assessment of the treatment effect in the study
protocol, without any scientific justification.
Bridging Studies
In recent years, the influence of ethnic factors 
on clinical outcomes for evaluation of efficacy
and safety of study medications under investiga-
tion has attracted much attention from regula-
tory authorities, especially when the sponsor is
interested in bringing forward an approved drug
product from the original region (e.g. the USA or
European Union) to a new region (e.g. Asia-Pacific
region). To determine if clinical data generated
from the original region are acceptable in the new
region, the International Conference on Harmo-
nization (ICH) has issued a guideline on ethnic
factors in the acceptability of foreign clinical
data.20 The purpose of this guideline is not only
to permit adequate evaluation of the influence of
ethnic factors, but also to minimize duplication
of clinical studies in the new region. This guide-
line is known as the ICH E5 guideline.
As indicated in the ICH E5 guideline, a bridg-
ing study is defined as a study performed in the
new region to provide pharmacokinetic, phar-
macodynamic, or clinical data on efficacy, safety,
dosage, and regimen in the new region, which will
allow extrapolation of the foreign clinical data to
the population in the new region. The ICH E5
guideline suggests that the regulatory authority
of the new region assesses the ability to extrapo-
late foreign data based on the bridging data pack-
age, which consists of: (1) information including
pharmacokinetic data and any preliminary phar-
macodynamic and dose–response data from the
complete clinical data package (CCDP), which is
relevant to the population of the new region; and
if needed, (2) a bridging study to extrapolate the
foreign efficacy and/or safety data to the new re-
gion. The ICH E5 guideline indicates that bridg-
ing studies may not be necessary if the study
drugs are insensitive to ethnic factors. For drugs
that are characterized as insensitive to ethnic fac-
tors, the type of bridging studies (if needed) will
depend on experience with the drug class and on
the likelihood that extrinsic ethnic factors will af-
fect the drug’s safety, efficacy and dose response.
On the other hand, for drugs that are ethnically
sensitive, a bridging study is usually needed since
the populations in the two regions are different.
In the ICH E5 guideline, however, no criteria for
assessment of the sensitivity to ethnic factors for
determining whether a bridging study is needed
are provided. Moreover, when a bridging study is
conducted, the ICH guideline indicates that the
study is readily interpreted as capable of bridging
the foreign data if it shows that dose response,
safety, and efficacy in the new region are similar
S.C. Chow, et al
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to those in the original region. However, the ICH
does not clearly define the similarity.
Shih has interpreted this as consistency among
study centers by treating the new region as a new
center of multicenter clinical trials.21 Under this
definition, Shih proposed a method for assess-
ment of consistency to determine whether the
study is capable of bridging the foreign data to
the new region. Alternatively, Shao and Chow
proposed the concepts of reproducibility and gen-
eralizability probabilities for assessment of bridg-
ing studies.22 If the influence of the ethnic factors
is negligible, then we may consider the repro-
ducibility probability to determine whether the
clinical results observed in the original region are
reproducible in the new region. If there is a no-
table ethnic difference, the generalizability prob-
ability can be assessed to determine whether the
clinical results in the original region can be gen-
eralized in a similar, but slightly different patient
population as a result of a difference in ethnic
factors. In addition, Chow et al proposed assess-
ment of bridging studies based on the concept 
of population (or individual) bioequivalence.17
Along the same lines, Hung, alone and with oth-
ers, considered the assessment of similarity based
on testing for noninferiority between a bridging
study conducted in the new region, compared
with the previous study conducted in the original
region.23,24 This led to arguments regarding the
selection of a noninferiority margin.25 Note that
other methods such as the use of the Bayesian
approach have also been proposed.26
Test for consistency
For assessment of similarity between a bridging
study conducted in a new region and studies
conducted in the original region, Shih consid-
ered all of the studies conducted in the original
region as a multicenter trial and proposed to test
consistency among study centers by treating the
new region as a new center of a multicenter
trial.21
Suppose that there are K reference studies in
the CCDP. Let Ti denote the standardized treat-
ment group difference, i.e.
where is the sample mean of mTi(mCi) 
observations in the treatment (control) group,
and si is the pooled sample SD. Shih considered
the following predictive probability for testing
consistency:21
Test for reproducibility and generalizability
When the ethnic difference is negligible, Shao and
Chow suggested assessing reproducibility proba-
bility for similarity between clinical results from
a bridging study and studies conducted in the
CCPD.22 Let x be a clinical response of interest 
in the original region. Let y be similar to x, but 
a response in a clinical bridging study conducted
in the new region. Suppose the hypotheses of 
interest are:
We reject H0 at the 5% level of significance if and
only if where tn−2 is the (1 − a/2)th per-
centile of the t distribution with n − 2 degrees of
freedom, n = n1 + n2,
and and are sample means and vari-
ances for the original region and the new region,
respectively. Thus, the power of T is given by:
where
and denotes the cumulative distribu-
tion function of the non-central t distribution with
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n–2 degrees of freedom and the non-centrality
parameter q. Replacing q in the power function
with its estimate T(x), the estimated power
is defined as a reproducibility probability for a
future clinical trial with the same patient popula-
tion. Note that when the ethnic difference is no-
table, Shao and Chow recommended assessing
the so-called generalizability probability for sim-
ilarity between clinical results from a bridging
study and studies conducted in the CCPD.22
Test for similarity
Using the criterion for assessment of population
(individual) bioequivalence, Chow et al proposed
the following measure of similarity between x
and y:17
where x is an independent replicate of x, and 
y, x and x are assumed to be independent. Since
a small value of q indicates that the difference
between x and y is small (relative to the differ-
ence between x and x), similarity between the
new and original regions can be claimed if and
only if q < qU, where qU is a similarity limit. Thus,
the problem of assessing similarity becomes a
problem of testing the following hypotheses:
Let k = 0 indicate the original region and k = 1 in-
dicate the new region. Suppose that there are mk
study centers and nk responses in each center for
a given variable of interest. For simplicity, we
only consider the balanced case in which centers
in a given region have the same number of ob-
servations. Let zijk be the ith observation from the
jth center of region k, let bjk be the between-center
random effect, and let eijk be the within-center
measurement error. Assume that
where mk is the population mean in region k, 
and {bjk} and {eijk}
are independent. Under the above model, the
criterion for similarity becomes
where is the total variance 
(between-center variance plus within-center vari-
ance) in region k. The above hypotheses are
equivalent to
where
Remarks
Liu et al proposed a Bayesian approach to use a
normal prior to taking up the strength from
CCDP for the evaluation of similarity between
the new and original regions.26 Their approach,
however, has been criticized in cases where there
is a serious imbalance in the information pro-
vided between the new and original regions.
Alternatively, Hsiao et al considered a mixture
model for the prior information (which is a
weighted average of a non-informative prior and
a normal prior) based on the concept of positive
treatment effect.27 Note that a group sequential
method and a two-stage design for assessment of
similarity between the new and original regions
has also been proposed.28,29
Concluding Remarks
Translational medicine is a multidisciplinary en-
tity that bridges basic scientific research with clin-
ical development. As the expense in developing
therapeutic pharmaceutical compounds continues
to increase and the success rates for getting such
compounds approved for marketing and to the
patients needing these treatments continues to
decrease, a focused effort has emerged in improv-
ing the communication and planning between
basic and clinical science. This will likely lead to
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more therapeutic insights being derived from new
scientific ideas, and more feedback being pro-
vided back to research so that its approaches are
better targeted. Translational medicine spans all
the disciplines and activities that lead to making
key scientific decisions as a compound traverses
across the difficult preclinical–clinical divide.
Many argue that improvement in making correct
decisions on which dose and regimen should be
pursued in the clinic, the likely human safety
risks of a compound, the likely drug interactions,
and the pharmacologic behavior of the com-
pound, are likely to be the most important deci-
sions made in the entire development process.
Many of these decisions and the path for uncov-
ering this information within later development
are defined at this specific time within the drug
development process. Improving these decisions
will likely lead to a substantial increase in the
number of safe and effective compounds available
to combat human diseases.
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